The US Food and Drug Administration (FDA) is cautioning physicians to avoid use of the drug boceprevir to treat hepatitis C in patients who are concurrently taking one of several protease inhibitors used to treat HIV/AIDS. Use of boceprevir in such patients can reduce the effectiveness of these medications, the FDA said.
Many patients with HIV are also infected with hepatitis C virus (HCV), particularly those who have a history of injecting illicit drugs. The presence of both viruses can contribute to poorer outcomes for coinfected patients, such as more rapid onset of HCV complications such as liver disease and liver cancer, according to the US Centers for Disease Control and Prevention (http://tinyurl.com/6u7eqb8).
Kuehn BM. Hepatitis Drug Reduces Effects of HIV Medications. JAMA. 2012;307(20):2138. doi:10.1001/jama.2012.5417